receptor targets raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
13 June – Science and the 2022 Russian invasion of Ukraine:Groups of academics report how global science community could help Ukraine via an action plan, including for helping organizing (re)vitalization of Ukrainian science and reconstruction in the future. On the same day, a researcher outlined a number of possible major policy-based actions that could mitigate the energy and resource crises caused or exacerbated by the war. Russian space agency Roscosmos announces the intent to, unilaterally and hazardously, take over paused telescope eROSITA, launched in collaboration with Germany (4 June). A science journalist outlines some of the food system-related environmental impacts of the war (21 June). A study reports a number of humanitarian, economic, and financial impacts of the war (23 June). 15 June Astronomers identify J1144 as the fastest-growing black hole of the last nine billion years, consuming matter equivalent to one Earth every second, as well as being the most luminous quasi-stellar object of that period. Researchers report Lac-Phe as the most significantly induced circulating metabolite in two animal models of exercise which – including via chronic administration – reduces food intake and suppresses obesity. 20 June A study suggests global food miles CO2 emissions are 3.5–7.5 times higher than previously estimated, with transport accounting for about 19% of total food-system emissions, albeit shifting towards plant-based diets remains substantially more important.
=== Hepcidin === Decreased serum and urine hepcidin levels are early indicators of iron deficiency. Hepcidin concentrations are also connected to the complex relationship between malaria and iron deficiency.
Korolev was buoyed by the first successful launches of the R-7 rocket in August and September, which paved the way for the launch of Sputnik 1. Word came that the US was planning to announce a major breakthrough at an International Geophysical Year conference at the National Academy of Sciences in Washington D.C., with a paper titled "Satellite Over the Planet", on October 6, 1957. Korolev anticipated that von Braun might launch a Jupiter-C with a satellite payload on or around October 4 or 5, in conjunction with the paper. He hastened the launch, moving it to October 4. The launch vehicle for PS-1 was a modified R-7 – vehicle 8K71PS number M1-PS – without much of the test equipment and radio gear that was present in the previous launches. It arrived at the Soviet missile base Tyura-Tam in September and was prepared for its mission at launch site number one. The first launch took place on Friday, October 4, 1957, at exactly 10:28:34 pm Moscow time, with the R-7 and the now named Sputnik 1 satellite lifting off the launch pad and placing the artificial "moon" into an orbit a few minutes later. This "fellow traveler", as the name is translated in English, was a small, beeping ball, less than two feet in diameter and weighing less than 200 pounds. But the celebrations were muted at the launch control center until the down-range far east tracking station at Kamchatka received the first distinctive beep ... beep ... beep sounds from Sputnik 1's radio transmitters, indicating that it was on its way to completing its first orbit.
When the alkali metals react with the heavier elements in the carbon group (silicon, germanium, tin, and lead), ionic substances with cage-like structures are formed, such as the silicides M4Si4 (M = K, Rb, or Cs), which contains M+ and tetrahedral Si4−4 ions. The chemistry of alkali metal germanides, involving the germanide ion Ge4− and other cluster (Zintl) ions such as Ge2−4, Ge4−9, Ge2−9, and [(Ge9)2]6−, is largely analogous to that of the corresponding silicides. Alkali metal stannides are mostly ionic, sometimes with the stannide ion (Sn4−), and sometimes with more complex Zintl ions such as Sn4−9, which appears in tetrapotassium nonastannide (K4Sn9). The monatomic plumbide ion (Pb4−) is unknown, and indeed its formation is predicted to be energetically unfavourable; alkali metal plumbides have complex Zintl ions, such as Pb4−9. These alkali metal germanides, stannides, and plumbides may be produced by reducing germanium, tin, and lead with sodium metal in liquid ammonia.
Sources: en.wikipedia.org
For instance, more public officials are brought within the scope of the directive, and EU member states are required to establish new registries of "beneficial owners" (i.e., those who ultimately own or control each company) which will impact banks. AMLD IV became effective 25 June 2015. On 24 January 2019, the European Commission sent official warnings to ten member states as part of a crackdown on lax application of money laundering regulations. The Commission sent Germany a letter of formal notice, the first step of the EU legal procedure against states. Belgium, Finland, France, Lithuania, and Portugal were sent reasoned opinions, the second step of the procedure which could lead to fines. A second round of reasoned opinions was sent to Bulgaria, Cyprus, Poland, and Slovakia. The ten countries have two months to respond or face court action. The commission had set a 26 June 2017 deadline for EU countries to apply new rules against money laundering and terrorist financing. On 13 February 2019, the Commission added Saudi Arabia, Panama, Nigeria and other jurisdictions to a blacklist of nations that pose a threat because of lax controls on terrorism financing and money laundering. This is a more expansive list than that of FATF.
The full text of Medea at Wikisource (multiple English translations) Structure of the tragedy. ClassicNotes about "Medea" The Medea of the modern times Cultural Organization "Theatre Arcadia" link to photographs and reviews of Medea directed by George Eugeniou at Theatro Technis and Angelique Rockas in the title role Medea public domain audiobook at LibriVox see the famous 3rd Choral ode of Medea from the Olivia Sutherland Medea
== Introduction == Theoretical calculation for the proton and neutron drip lines show that there would be about 7,000 nuclides that are between the drip lines, and containing 2 to 120 protons. There are presently 251 known stable nuclides. Many of these in theory could decay through spontaneous fission, alpha decay, double beta decay, etc. with a very long half-life, but this has not yet been observed. Thus, the number of stable nuclides is subject to change if some of these 251 have radioactive decay observed in the future. In this article, the "stable" nuclides are divided into three tables: one for nuclides that are theoretically stable (meaning no decay mode is possible) except to spontaneous fission, which is not considered plausible in this mass range; one for nuclides that can theoretically undergo forms of decay other than spontaneous fission but have no published lower bound on lifetime from experimental evaluations; and one for nuclides that can theoretically decay and have been examined without detecting any decay, allowing a lower bound to be published. In this last table, where a decay has been predicted theoretically but never observed experimentally (either directly or by finding an excess of the daughter), the theoretical decay mode is given in parentheses, and "> (lifetime in years)" is shown in the half-life column to show this lower limit in scientific notation. Such nuclides are considered to be "stable", also called "observationally stable" indicating the tentative nature of the conclusion, until some decay has been observed.
In males, puberty begins with the enlargement of the testicles and scrotum. The penis also increases in size, and a male develops pubic hair. A male's testicles also begin making sperm. The release of semen, which contains sperm and other fluids, is called ejaculation. During puberty, a male's erect penis becomes capable of ejaculating semen and impregnating a female. A male's first ejaculation is an important milestone in his development. On average, a male's first ejaculation occurs at age 13. Ejaculation sometimes occurs during sleep; this phenomenon is known as a nocturnal emission.
=== Chemical industry === Many chemicals exhibit a specific rotation as a unique property (an intensive property like refractive index or specific gravity) which can be used to distinguish it. Polarimeters can identify unknown samples based on this if other variables such as concentration and length of sample cell length are controlled or at least known. This is used in the chemical industry. By the same token, if the specific rotation of a sample is already known, then the concentration and/or purity of a solution containing it can be calculated. Most automatic polarimeters make this calculation automatically, given input on variables from the user.
Sources: en.wikipedia.org
=== Bioinorganic chemistry === In bioinorganic chemistry and bioorganometallic chemistry, coordination complexes serve either structural or catalytic functions. An estimated 30% of proteins contain metal ions. Examples include the intensely colored vitamin B12, the heme group in hemoglobin, the cytochromes, the chlorin group in chlorophyll, and carboxypeptidase, a hydrolytic enzyme important in digestion. Another complex ion enzyme is catalase, which decomposes the cell's waste hydrogen peroxide. Synthetic coordination compounds are also used to bind to proteins and especially nucleic acids (e.g. anticancer drug cisplatin).
The most common uses for enzyme inhibitors are as drugs to treat disease. Many of these inhibitors target a human enzyme and aim to correct a pathological condition. For instance, aspirin is a widely used drug that acts as a suicide inhibitor of the cyclooxygenase enzyme. This inhibition in turn suppresses the production of proinflammatory prostaglandins and thus aspirin may be used to reduce pain, fever, and inflammation. As of 2017, an estimated 29% of approved drugs are enzyme inhibitors of which approximately one-fifth are kinase inhibitors. A notable class of kinase drug targets is the receptor tyrosine kinases which are essential enzymes that regulate cell growth; their over-activation may result in cancer. Hence kinase inhibitors such as imatinib are frequently used to treat malignancies. Janus kinases are another notable example of drug enzyme targets. Inhibitors of Janus kinases block the production of inflammatory cytokines and hence these inhibitors are used to treat a variety of inflammatory diseases in including arthritis, asthma, and Crohn's disease. An example of the structural similarity of some inhibitors to the substrates of the enzymes they target is seen in the figure comparing the drug methotrexate to folic acid. Folic acid is the oxidised form of the substrate of dihydrofolate reductase, an enzyme that is potently inhibited by methotrexate. Methotrexate blocks the action of dihydrofolate reductase and thereby halts thymidine biosynthesis.
=== Other benefits === Against the background of the overwhelmingly negative effects of smoking on health, some observational studies have suggested that smoking might have specific beneficial effects, including in the field of cardiovascular disease. Interest in this epidemiological phenomenon has also been aroused by COVID-19. Systematic review of reports that suggested smokers respond better to treatment for ischemic stroke provided no support for such claims. Claims of surprising benefits of smoking, based on observational data, have also been made for Parkinson's disease, as well as a variety of other conditions, including basal-cell carcinoma, melanoma, acute mountain sickness, pemphigus, celiac disease, and ulcerative colitis, among others. Tobacco smoke has many bioactive substances, including nicotine, that are capable of exerting a variety of systemic effects. Surprising correlations may also stem from non-biological factors such as residual confounding (that is to say, the methodological difficulties in completely adjusting for every confounding factor that can affect outcomes in observational studies). For example, in his book Probably Overthinking It, the author Allen B. Downey dissects how a misinterpretation of data on low birth weight of babies born to smoking mothers delayed public-health recommendations against smoking during pregnancy by almost a decade.
A transaminase converts the oxaloacetate to aspartate for transport back across the membrane and into the intermembrane space. In oxidative phosphorylation, the passage of electrons from NADH and FADH2 through the electron transport chain releases the energy to pump protons out of the mitochondrial matrix and into the intermembrane space. This pumping generates a proton motive force that is the net effect of a pH gradient and an electric potential gradient across the inner mitochondrial membrane. Flow of protons down this potential gradient – that is, from the intermembrane space to the matrix – yields ATP by ATP synthase. Three ATP are produced per turn. Although oxygen consumption appears fundamental for the maintenance of the proton motive force, in the event of oxygen shortage (hypoxia), intracellular acidosis (mediated by enhanced glycolytic rates and ATP hydrolysis), contributes to mitochondrial membrane potential and directly drives ATP synthesis. Most of the ATP synthesized in the mitochondria will be used for cellular processes in the cytosol; thus it must be exported from its site of synthesis in the mitochondrial matrix. ATP outward movement is favored by the inner mitochondrial membrane's electrochemical potential because the cytosol has a relatively positive charge compared to the relatively negative matrix. For every ATP transported out, it costs 1 H+. Producing one ATP costs about 3 H+. Therefore, making and exporting one ATP requires 4H+.
=== GLC (1981–1985) === The equivalent American Mazda GLC (Great Little Car) appeared in the 1981 model year, although the rear-wheel drive wagon also continued to be offered. It was only offered with a single engine – the twin-barrel 1.5-litre with 68 hp (51 kW)—and lasted through 1985, after which it was replaced by the next-generation Mazda 323. With this, the GLC nameplate was retired. The BD was the only front-wheel drive Mazda vehicle using the GLC name. Originally it was offered with three- or five-door bodywork, in standard, Custom, Custom L, or Sport equipment levels. The five-door only came as a Custom and was sold only in Hawaii and Puerto Rico. All cars received exposed rectangular sealed-beam units. The later four-door saloon, introduced for 1983, was available in Custom, Custom L, and Sport models. The Sport received blacked out trim, a steering wheel borrowed from the RX-7, full instrumentation, and a special rear interior which closely integrates the side trim with the rear seat design – an early iteration of a design philosophy taken to its extreme with the 1988 Persona and the 1990 Eunos Cosmo. Unlike the sporting 323s in other markets, the Sport only received special hubcaps, rather than alloy wheels. For 1982, the Sport was made to live up to its name a little bit more, with the installation of a front anti-roll bar and cast aluminum wheels. The five-door GLC gained a fully carpeted trunk for 1982.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。